Backbone-cyclized, disulfide-rich peptides like cyclotides and θ-defensins are exceptionally stable, cell-permeable scaffolds that could enable a new generation of peptide drugs targeting previously undruggable protein interactions.
Cell membrane permeability + extreme stabilityUnlike linear peptides, backbone-cyclized polypeptides resist degradation and cross cell membranes, enabling them to reach intracellular drug targets that are inaccessible to most peptide therapeutics.
What the researchers found
Backbone-cyclized, cysteine-rich polypeptides — including cyclotides, θ-defensins, and sunflower trypsin inhibitor peptides — serve as exceptionally stable molecular scaffolds for designing new drugs and bioimaging tools. These cyclic peptides are far more resistant to chemical, thermal, and biological degradation than linear peptides. They tolerate extensive sequence modification while maintaining structure, can cross cell membranes, and can modulate intracellular protein-protein interactions both in vitro and in vivo.
Why it matters
Traditional peptide drugs break down quickly in the body and can't enter cells. Backbone-cyclized peptides overcome both limitations — their circular structure with disulfide bonds makes them nearly indestructible, and many can cross cell membranes to reach intracellular targets. This makes them ideal starting points for designing drugs that target protein-protein interactions, which are notoriously difficult to block with conventional small-molecule drugs.
The numbers in context
Review covers cyclotides, θ-defensins, and sunflower trypsin inhibitor (SFTI) peptides · enhanced chemical, thermal, and biological stability · cell membrane permeability · tolerance to sequence variability
How the study worked
This is a review article providing an overview of recent developments in using three classes of disulfide-rich, backbone-cyclized polypeptides (cyclotides, θ-defensins, and sunflower trypsin inhibitor peptides) as molecular scaffolds for drug design and bioimaging applications.
Who was studied
Review of peptide scaffold technologies (no patient population)
What this study cannot tell us
As a review, no new experimental data are presented. While these scaffolds show promise in preclinical studies, few backbone-cyclized peptide drugs have advanced to clinical trials. Manufacturing scalability and cost for complex cyclic peptides remain challenges. The review does not address potential immunogenicity concerns with therapeutic use.
How to read the evidence
This is a review article summarizing the state of the field for cyclic peptide scaffolds. It provides a comprehensive overview of the technology but does not present new experimental data. The underlying studies cited range from in vitro characterization to in vivo proof-of-concept.
When this study was published
Published in 2019, this review captures the cyclic peptide scaffold field at an active stage of development. Since then, several cyclic peptide drug candidates have advanced further in preclinical and early clinical development.
The bigger picture
The development of cyclic peptide scaffolds addresses the fundamental limitations that have historically kept peptides from becoming mainstream drugs. By combining the specificity and low toxicity of peptides with the stability and cell permeability of small molecules, these scaffolds represent a 'best of both worlds' approach. As the technology matures, it could dramatically expand the druggable proteome by enabling targeting of intracellular protein-protein interactions.
Questions still open
- Which of the three scaffold types (cyclotides, θ-defensins, SFTI) is most practical for therapeutic development in terms of manufacturing and cost?
- Can backbone-cyclized peptide scaffolds be made orally bioavailable, eliminating the need for injection?
- How do these engineered cyclic peptides perform in terms of immunogenicity and long-term safety in animal models?
Common questions
What makes cyclic peptides so much more stable than regular peptides?
What are cyclotides and where do they come from?
Read the original research
Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions.
The Biochemical journal, 476(1), 67-83
Citation
Chaudhuri, Dipankar; Aboye, Teshome; Camarero, Julio A. (2019). Using backbone-cyclized Cys-rich polypeptides as molecular scaffolds to target protein-protein interactions.. The Biochemical journal, 476(1), 67-83. https://doi.org/10.1042/BCJ20180792